Governance
Governance of the ASSG occurs through an Executive and Board of Directors. The Executive comprises the Group Chair, two Deputy Chairs, Executive Officer and Director of the Centre for Biostatistics and Clinical Trials (BaCT). The Board of Directors was formally installed in August 2008 with two additional directors appointed in 2009. Of the current eight Directors, seven are medically trained and one member is a consumer representative. The following profiles showcase the wealth of experience and knowledge that these Directors bring to the board table.
Associate Professor David Thomas (Chairman), Melbourne-based, is a senior medical oncologist, NHMRC Senior Research Fellow and Head of the Sarcoma Genomics and Genetics laboratory and the Medical Oncology Team for Sarcoma at the Peter MacCallum Cancer Centre. David’s research focuses on a strong cell and molecular program, which forms the basis of early phase and translational clinical research.
Mr Marcus Boyson, Sydney-based, is a Director of Deutsche Bank, Sydney and head of the Strategic Hedge Group for Australia and New Zealand. His team of five people covers liability management across foreign exchange, commodities and interest rates. Marcus holds a Bachelor of Commerce Degree majoring in Economics from the University of Melbourne and has completed the Commonwealth Bank Financial Markets Graduate program.
Professor Peter Choong, Melbourne-based, is a Director and Professor of Orthopaedics at St. Vincent’s Hospital and Peter MacCallum Cancer Centre; Chair of the Sarcoma Service in Melbourne; and the Sir Hugh Devine Chair of Surgery and Head University Melbourne Department of Surgery at St. Vincent’s Hospital. Peter’s close clinical and research association with other sarcoma experts places him in an ideal position to develop strategies to translate programs of basic research into programs of clinical care.
Professor Phil Crowe, Sydney-based, is a Professor of Surgery and Clinical Associate Dean at the University of New South Wales and Head of Department of General Surgery at the Prince of Wales Hospital. Phil’s major surgical interests are sarcoma, breast and endocrine surgery. He has published widely on subjects such as prognostic factors and outcomes in soft tissue sarcoma, colorectal cancer, thyroid surgery breast cancer treatment, as well as on surgical education.
Dr Jayesh Desai, Melbourne-based, is a Medical Oncologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre; Senior Clinical Research Fellow within the Ludwig Colon Cancer Initiative program; and Associate Director for Cancer Trials Australia. Jayesh’s clinical and research interests are in rationally developing new anticancer therapeutics with particular emphasis on sarcomas and colorectal cancer.
Dr Warren Joubert, Brisbane-based, is a Medical Oncologist at the Princess Alexandra and Greenslopes Private Hospitals. His clinical and research interests include sarcoma and gastro-intestinal cancers and he is a principal investigator and associate investigator for a number of related clinical trials at these sites. He is also an active member of the newly formed Adolescent and Young Adult Cancer service at the Princess Alexandra Hospital.
Associate Professor Susan Neuhaus, Adelaide-based, is a Surgical Oncologist and Clinical Associate Professor at the Royal Adelaide Hospital and current Chair of the Surgical Oncology Group of COSA. Susan’s main clinical and research interests are melanoma and sarcoma while her basic research includes a PhD investigating mechanisms of tumour dissemination during laparoscopic surgery. Publications include work on radiation-induced sarcoma, retroperitoneal liposarcomas, regional chemotherapy and gastro-intestinal stromal tumours.
Dr Marianne Phillips, Perth-based, is a Consultant Paediatric and Adolescent Oncologist and Palliative Care Specialist at Princess Margaret Hospital for Children. Originally from the UK, Marianne has developed an increasing interest in the specific needs of adolescent oncology patients and has been instrumental in establishing the first specific adolescent oncology inpatient facilities in Australia. She is lead clinician for the Western Australian Cancer and Palliative Care Network paediatric and adolescent tumour collaborative and a member of that network’s sarcoma tumour collaborative.
Professor Martin Tattersall, Sydney-based, has since 1977 been Professor of Cancer Medicine at the University of Sydney and a clinical academic oncologist at Royal Prince Alfred Hospital. His clinical and research interests include sarcomas, clinical trials, cancer education, doctor/patient communication and supportive care. He has been President of COSA and was Chairman of the Australian Drug Evaluation Committee for 13 years. He has supervised close to 20 PhD and MD students.
Last update: 09-Jun-2011 05:02 PM
